Sinclair at TIME100: A 150-Year Lifespan, and a Warning About Peptides

Harvard Medical School geneticist David Sinclair took the stage at the TIME100 Health Leadership Forum in New York City on September 10, where he was asked to defend one of his most-quoted predictions: that the first person to live to 150 is already alive today.

The 150-Year Claim, Revisited

Pressed by TIME executive editor Nikhil Kumar on what motivates the claim, Sinclair pointed to the pace of change rather than to any single breakthrough. "Children born today will live into the 22nd century, and just think about in the last five years what's happened to our world; it's barely recognizable when it comes to AI and even the healthcare world," he said. Children born now, he argued, will have access to technologies "that we literally cannot even imagine now."

A Warning About the Biohacking Fringe

Notably, Sinclair used the panel to voice concern about the direction of consumer longevity culture. He said behaviors once considered fringe — injecting peptides, taking drugs not yet proven effective in humans — are becoming routine. "I wonder where we're going to go," he said.

He stopped short of calling for tighter rules. Sinclair said he applauds the right of patients, working with their doctors, to try something when nothing else works and there is no apparent downside, adding that regulations five years ago were so strict that suffering patients could not access medicines. "That was too extreme in my view, but we've gone with the other extreme."

The Credibility Problem on Stage

Sinclair was joined by neuroscientist Jennifer Garrison, whose longevity research centers on ovarian aging and women's health, and Jack Jia, founder and CEO of the telehealth platform Musely, which sponsored the event. Garrison was blunter than Sinclair about the state of the field: "there's a little bit of a credibility issue in the longevity space, and a lot of the products that are marketed are either poorly supported by evidence or outright pseudoscience." The hard part for consumers, she said, is telling the difference.

Garrison also argued that research has systematically underweighted female physiology, leaving the field "generations behind" on the underlying data.

What It Means

Sinclair remains one of longevity science's most visible optimists, and his 150-year prediction continues to draw criticism from researchers who see it as far ahead of the evidence. What is new here is the framing: a leading advocate for radical life extension publicly flagging the unproven-intervention market that has grown up around his own field. Readers weighing longevity products should note that a panel of insiders spent much of its time on stage discussing how little of that market is evidence-backed.